Compare Lennar Corporation (LEN) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Oruka Therapeutics Inc. Common Stock — how do they compare? Lennar Corporation trades at $74.77 (market cap $17.81B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Lennar Corporation is far larger — about 3.4× Oruka Therapeutics Inc. Common Stock's market cap, and Lennar Corporation pays a 2.67% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lennar Corporation for 67 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| LEN | ORKA | |
|---|---|---|
Market Cap | $17.81B | $5.18B |
Volume | 4,102,017 | 490,798 |
Sector | Consumer Cyclical | Health |
52-Week High | $133.13 | $113.08 |
52-Week Low | $73.53 | $26.19 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $22.23B | $4.31B |
Dividend Yield | 2.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar Corporation (LEN) trades at $74.92, showing modest daily gains but facing bearish technical signals with recent earnings misses. The stock trades below book value (P/B 0.83) with reasonable P/E of 14.19, while revenue declined to $34.19B in 2025 with net income margin compressing to 6.07%. Berkshire Hathaway's significant stake accumulation to 11.2% provides institutional support despite recent negative news flow.
The outlook remains challenged by housing market headwinds and margin pressure, but deep value characteristics and Berkshire's backing offer potential upside to the $77.38 consensus target. Key risks include persistent earnings misses, rising mortgage rates, and the Hunterbrook short report allegations regarding Millrose transactions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
